Navigation Links
Pathway Diagnostics Announces Commercial Availability of Second Generation SensiTrop(TM) II Molecular HIV Co-receptor Tropism Assay
Date:5/7/2008

SensiTrop II accurately classifies Dual/Mixed tropic HIV patients with

samples provided by Pfizer.

MALIBU, Calif., May 7 /PRNewswire/ -- Pathway Diagnostics announces nationwide availability of its patented second generation molecular SensiTrop(TM) II assay, combining the sensitivity of molecular heteroduplex tracking assay (HTA) technology with the specificity of molecular sequencing for determining the co-receptor tropism status of HIV infected patients. Pathway performs the SensiTrop(TM) II assay in its CLIA-certified laboratory on samples received from national reference laboratories in the U.S. and Delphic Diagnostics in Europe.

On April 28th Pathway presented data during the 2008 Clinical Virology Symposium comparing SensiTrop II with Monogram's Trofile(TM) assay. The performance of SensiTrop II was examined using 100 HIV treatment experienced patient samples provided by Pfizer and previously tested by the Trofile(TM) assay. SensiTrop II classified 41 samples as Dual/Mixed (D/M) tropic, 9 of these samples were classified as R5-tropic by Trofile. Maraviroc's phase III data stated Trofile misclassified 7-9% of patients as CCR5, similar to the results obtained in the present study.

SensiTrop II is available nationwide through national reference laboratories and is also being utilized in CCR5 compound clinical trials. "Pathway is pleased to introduce its second generation molecular HIV tropism assay nationwide, providing clinicians a fast (less than 7 days), accurate, sensitive and economical testing alternative to the currently available biological HIV tropism assay," said Walter Narajowski, Pathway Diagnostics President and CEO. "We are especially pleased with improvements in sample amplification that enable SensiTrop II to provide results from more than 95% of samples received."

SensiTrop II is the first HIV genotype co-receptor tropism test that combines the sensitivity of HTA and the specificity of DNA sequence analysis. "We are excited by the outcome of this study, and that our combined molecular approach demonstrates excellent concordance with the Trofile assay on the samples provided by Pfizer," said Terry Robins Ph.D., Vice President of Research and Development at Pathway Diagnostics.

About HIV Co-receptor tropism

The ability of the HIV virus to infect different cell types utilizing different cell surface receptors is referred to as HIV co-receptor tropism. One type of HIV that utilizes the CCR5 co-receptor has been shown to be blocked by CCR5 antagonist drugs, such as Selzentry. A different type of HIV that utilizes the CXCR4 co-receptor is not blocked by CCR5 antagonists. Therefore, determining the tropism status of HIV-infected patients has been indicated by the FDA before initiating CCR5 antagonist therapy.

About Pathway Diagnostics

Pathway Diagnostics Corporation provides biomarker development and laboratory testing services for pharmaceutical company's drug development programs. The company combines assay development expertise with a broad range of advanced technology platforms, a fully licensed CLIA laboratory, and a growing portfolio of patent-protected biomarkers for pharmaceutical companies to use in drug development and for commercial reference laboratories and in vitro diagnostic manufacturers to license for use in patient testing. Pathway effectively bridges the gap between biomarker research and biomarker commercialization, as well as ensures a regulatory-compliant environment for laboratory testing for preclinical and clinical drug development programs leading to future companion diagnostics.


'/>"/>
SOURCE Pathway Diagnostics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimers Disease
2. Ingenuity Systems and Pfizer Announce Strategic Partnership for Pathway Analysis
3. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
4. Pathway Medical Technologies Names Paul Buckman Chairman of the Board of Directors
5. Genetic pathway critical to disease, aging found
6. AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test
7. Pathway Diagnostics Announces Patent Issuance for the Diagnostic Measurement of HIV Tropism for the Initiation or Modification of HIV Therapy
8. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
11. DxTech and Nicholas Piramal in POC Diagnostics Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only ... Center and will showcase its product’s latest features from June 26 to June ... scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining centers ... The result of a collaboration among several companies with expertise in toolholding, cutting ...
(Date:6/23/2016)... June 23, 2016 ReportsnReports.com ... report to its pharmaceuticals section with historic and ... and much more. Complete report on ... pages, profiling 15 companies and supported with 261 ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global Cell ...
(Date:6/22/2016)... Research and Markets has announced the addition of the "Biomarkers: ... The global biomarkers market has grown ... market is expected to grow at a five-year compound annual growth ... billion in 2015 to $96.6 billion in 2020. ... 2020) are discussed. As well, new products approved in 2013 and ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... area for financial services, but it also plays a fundamental ...
Breaking Biology News(10 mins):